Low Energy Singlets in the Excitation Spectrum of the Spin Tetrahedra System Cu_2Te_2O_5Br_2

Low energy Raman scattering of the s=1/2 spin tetrahedra system Cu_2Te_2O_5Br_2 is dominated by an excitation at 18 cm^{-1} corresponding to an energy E_S=0.6\Delta, with \Delta the spin gap of the compound. For elevated temperatures this mode shows a soft mode-like decrease in energy pointing to an instability of the system. The isostructural reference system Cu_2Te_2O_5Cl_2 with a presumably larger inter-tetrahedra coupling does not show such a low energy mode. Instead its excitation spectrum and thermodynamic properties are compatible with long range Neel-ordering. We discuss the observed effects in the context of quantum fluctuations and competing ground states.Comment: 5 pages, 2 figures, ISSP-Kashiwa 2001, Conference on Correlated Electron

Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age

Retrospective histologic analyses of bone biopsies and of post mortem samples from normal persons of different age groups, and of bone biopsies of age- and sex-matched groups of patients with primary osteoporosis and aplastic anemia show characteristic age dependent as well as pathologic changes including atrophy of osseous trabeculae and of hematopoiesis, and changes in the sinusoidal and arterial capillary compartments. These results indicate the possible role of a microvascular defect in the pathogenesis of osteoporosis and aplastic anemia

Dzyaloshinsky-Moriya Spin Canting in the LTT Phase of La2-x-yEuySrxCuO4

The Cu spin magnetism in La2-x-yEuySrxCuO4 (x<=0.17; y<=0.2) has been studied by means of magnetization measurements up to 14 T. Our results clearly show that in the antiferromagnetic phase Dzyaloshinsky-Moriya (DM)superexchange causes Cu spin canting not only in the LTO phase but also in the LTLO and LTT phases. In La1.8Eu0.2CuO4 the canted DM-moment is about 50% larger than in pure La2CuO4 which we attribute to the larger octahedral tilt angle. We also find clear evidence that the size of the DM-moment does not change significantly at the structural transition at T_LT from LTO to LTLO and LTT. The most important change induced by the transition is a significant reduction of the magnetic coupling between the CuO2 planes. As a consequence, the spin-flip transition of the canted Cu spins which is observed in the LTO phase for magnetic field perpendicular to the CuO2 planes disappears in the LTT phase. The shape of the magnetization curves changes from the well known spin-flip type to a weak-ferromagnet type. However, no spontaneous weak ferromagnetism is observed even at very low temperatures, which seems to indicate that the interlayer decoupling in our samples is not perfect. Nonetheless, a small fraction (<15%) of the DM-moments can be remanently magnetized throughout the entire antiferromagnetically ordered LTT/LTLO phase, i.e. for T<T_LT and x<0.02. It appears that the remanent DM-moment is perpendicular to the CuO2 planes. For magnetic field parallel to the CuO2 planes we find that the critical field of the spin-flop transition decreases in the LTLO phase, which might indicate a competition between different in-plane anisotropies. To study the Cu spin magnetism in La2-x-yEuySrxCuO4, a careful analysis of the Van Vleck paramagnetism of the Eu3+ ions was performed.Comment: 22 pages, 27 figure

Case-control study on analgesics and nephropathy (SAN): protocol

BACKGROUND: The association between intake of non-phenacetin-containing analgesics and the occurrence of chronic renal failure is still controversially discussed. A new epidemiologic study was planned and conducted in Germany and Austria. METHODS/DESIGN: The objective of the international, multicenter case-control study was to evaluate the association between end-stage renal disease (ESRD) and use of non-phenacetin-containing analgesics with particular emphasis on combined formulations. A targeted sample of 1000 new (incident) dialysis patients, aged less than 50 years, was planned to recruit between January 1, 2001 and December 31, 2004. The age limit was chosen to avoid contamination of the study population with phenacetin-containing analgesics to the extent possible. Four control subjects per ESRD case, matched by age, sex, and region were selected from the population living in the region the case came from. Lifetime exposure to analgesics and potential renal risk factors were recorded in a single face-to-face interview. A set of aids was introduced to reinforce the memory of study participants. A standardized, pre-tested interview questionnaire (participants), a medical documentation sheet (physicians in dialysis centres), a logbook for all activities (dialysis centres) were used to collect the necessary data. Quality management consisted of the standardized procedures, (re-) training and supervision of interviewers, regular checks of all incoming data for completeness and plausibility. The study is scientifically independent and governed by a international Scientific Advisory Committee that bridged the gap between the sponsoring companies and the investigators. Also other advisory groups assisted the managing committee of the study. All relevant German and Austrian nephrological associations supported the study, and the study design was carefully reviewed and approved by the Kidney Foundation of Germany. DISCUSSION: The study is expected to answer the main research question by end 2005. There is however a high potential for various biases that we tried to address with adequate measure. One limitation however cannot be overcome: The methodologically needed age-limitation of the study will make it not easy to generalize the results to age groups over 50 years. It might be suggested to repeat the study for persons over 50 years in 10 years when contamination with phenacetin use early in life is likely to be outgrown

Analgesics use and ESRD in younger age: a case-control study

<p>Abstract</p> <p>Background</p> <p>An ad hoc peer-review committee was jointly appointed by Drug Authorities and Industry in Germany, Austria and Switzerland in 1999/2000 to review the evidence for a causal relation between phenacetin-free analgesics and nephropathy. The committee found the evidence as inconclusive and requested a new case-control study of adequate design.</p> <p>Methods</p> <p>We performed a population-based case-control study with incident cases of end-stage renal disease (ESRD) under the age of 50 years and four age and sex-matched neighborhood controls in 170 dialysis centers (153 in Germany, and 17 in Austria) from January 1, 2001 to December 31, 2004. Data on lifetime medical history, risk factors, treatment, job exposure and intake of analgesics were obtained in a standardized face-to-face interview using memory aids to enhance accuracy. Study design, study performance, analysis plan, and study report were approved by an independent international advisory committee and by the Drug Authorities involved. Unconditional logistic regression analyses were performed.</p> <p>Results</p> <p>The analysis included 907 cases and 3,622 controls who had never used phenacetin-containing analgesics in their lifetime. The use of high cumulative lifetime dose (3^rdtertile) of analgesics in the period up to five years before dialysis was not associated with later ESRD. Adjusted odds ratios with 95% confidence intervals were 0.8 (0.7 – 1.0) and 1.0 (0.8 – 1.3) for ever- compared with no or low use and high use compared with low use, respectively. The same results were found for all analgesics and for mono-, and combination preparations with and without caffeine. No increased risk was shown in analyses stratifying for dose and duration. Dose-response analyses showed that analgesic use was not associated with an increased risk for ESRD up to 3.5 kg cumulative lifetime dose (98 % of the cases with ESRD). While the large subgroup of users with a lifetime dose up to 0.5 kg (278 cases and 1365 controls) showed a significantly decreased risk, a tiny subgroup of extreme users with over 3.5 kg lifetime use (19 cases and 11 controls) showed a significant risk increase. The detailed evaluation of 22 cases and 19 controls with over 2.5 kg lifetime use recommended by the regulatory advisors showed an impressive excess of other conditions than analgesics triggering the evolution of ESRD in cases compared with controls.</p> <p>Conclusion</p> <p>We found no clinically meaningful evidence for an increased risk of ESRD associated with use of phenacetin-free analgesics in single or combined formulation. The apparent risk increase shown in a small subgroup with extreme lifetime dose of analgesics is most likely an indirect, non-causal association. This hypothesis, however, cannot be confirmed or refuted within our case-control study. Overall, our results lend support to the mounting evidence that phenacetin-free analgesics do not induce ESRD and that the notion of "analgesic nephropathy" needs to be re-evaluated.</p